Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FMEC6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,688
Award facts
- Contract value 100% obligated
- $23,688.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,688.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order was issued on December 29, 2025, with an ultimate completion date of January 21, 2026, and carries no set-aside designation. DMS Pharmaceutical Group is performing work at its facility in Park Ridge, Illinois, leveraging its established position as a critical supplier within the federal pharmaceutical supply chain, particularly for Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply to military healthcare facilities worldwide. The parent IDC, valued at $499.999 billion with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables. Xolair, an immunosuppressant biologic agent, represents the type of specialized pharmaceutical product that DMS Pharmaceutical Group regularly supplies to support the diverse medical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FMEC6?
SPE2DR26FMEC6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FMEC6 worth?
The government has obligated $23,688 on SPE2DR26FMEC6.
Is contract SPE2DR26FMEC6 an order under another contract?
Yes. SPE2DR26FMEC6 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEC6 competed?
The extent of competition for SPE2DR26FMEC6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award